San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, DNAlite Therapeutics is raising $8,929,986.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mubhij Ahmad played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DNAlite Therapeutics

DNAlite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed to creating a category of medicines overcoming constraints of current biological medicines. Powered by a proprietary vector technology, all of DNAlites medicines are designed to be oral and non-immunogenic; overcoming the shortcomings of current biologics. DNAlite is modifying the GI tract to restore its abilities in patients with genetic diseases or with compromised mucosa. We are harnessing our vector technology to carry DNA/RNA to the GI cells to fight intestinal and systemic diseases.

To learn more about DNAlite Therapeutics, visit http://www.dnalite.com/

Contact:
Mubhij Ahmad, Chief Executive Officer
713-569-0302
mubhij@dnalite.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved